302. Leber hereditary optic neuropathy Clinical trials / Disease details
Clinical trials : 23 / Drugs : 15 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 33
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05293626 (ClinicalTrials.gov) | January 2023 | 9/12/2021 | Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations | A Phase 1/2, Single-Arm, Open-Label, Dose-Finding Clinical Trial to Evaluate the Safety and Efficacy of Gene Therapy for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation | Leber Hereditary Optic Neuropathy (LHON) | Drug: NR082 Injection;Device: Injection needle | Neurophth Therapeutics Inc | NULL | Not yet recruiting | 18 Years | 75 Years | All | 18 | Phase 1/Phase 2 | NULL |